On Friday, Novavax, Inc (NASDAQ: NVAX) opened lower -5.66% from the last session, before settling in for the closing price of $7.07. Price fluctuations for NVAX have ranged from $3.90 to $23.86 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 516.28%. Company’s average yearly earnings per share was noted 141.64% at the time writing. With a float of $146.57 million, this company’s outstanding shares have now reached $160.42 million.
Considering the fact that the conglomerate employs 952 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 73.3%, operating margin of -35.6%, and the pretax margin is -25.89%.
Novavax, Inc (NVAX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Novavax, Inc is 8.87%, while institutional ownership is 59.67%. The most recent insider transaction that took place on Apr 14 ’25, was worth 24,406. Before that another transaction happened on Dec 13 ’24, when Company’s Director sold 4,150 for $9.02, making the entire transaction worth $37,435. This insider now owns 14,770 shares in total.
Novavax, Inc (NVAX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 141.64% per share during the next fiscal year.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Check out the current performance indicators for Novavax, Inc (NVAX). In the past quarter, the stock posted a quick ratio of 0.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit 0.19 in the next quarter and is forecasted to reach 0.35 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Compared to the last year’s volume of 5.12 million, its volume of 8.45 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 66.93%. Additionally, its Average True Range was 0.66.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 25.38%, which indicates a significant decrease from 59.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 141.11% in the past 14 days, which was higher than the 84.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.24, while its 200-day Moving Average is $9.89. Nevertheless, the first resistance level for the watch stands at $7.18 in the near term. At $7.70, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.23. If the price goes on to break the first support level at $6.14, it is likely to go to the next support level at $5.61. Now, if the price goes above the second support level, the third support stands at $5.09.
Novavax, Inc (NASDAQ: NVAX) Key Stats
There are currently 160,844K shares outstanding in the company with a market cap of 1.07 billion. Presently, the company’s annual sales total 682,160 K according to its annual income of -187,500 K. Last quarter, the company’s sales amounted to 88,310 K and its income totaled -81,030 K.
